<DOC>
	<DOCNO>NCT01604213</DOCNO>
	<brief_summary>The purpose study demonstrate combine vildagliptin-metformin therapy associate clinically significant reduction biological marker inflammation , pro-thrombogenicity , atherosclerosis compare metformin mono-therapy population diabetic patient coronary artery disease undergo cardiac rehabilitation . The pre-specified established biological marker inflammation , pro-thrombogenicity , atherosclerosis include : interleukin-6 ( IL-6 - primary biological marker ) , hs-CRP , platelet reactivity testing , MMP-9 , Interleukin 1 beta ( IL-1 beta ) adiponectin level .</brief_summary>
	<brief_title>Effects Vildagliptin/Metformin Combination Markers Atherosclerosis , Thrombosis , Inflammation Diabetics With Coronary Artery Disease</brief_title>
	<detailed_description>The study design single-center , randomize , non-blinded , clinical trial provide evidence effect vildagliptin key biomarkers atherothrombosis inflammation . We plan prospectively enroll 60 patient proven coronary artery disease randomize 2:1 ratio either vildagliptin-metformin therapy ( n=40 ) metformin therapy ( n=20 ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 Diabetes Mellitus oral monotherapy diet treatment Stable document ischemic Heart disease ( &gt; 30 day post AMI , CABG PCI ) Suboptimal Hb A1c define ≥6.5 % Age &gt; 21 Life expectancy &gt; 1 year Significant renal impairment ( creatinine ≥1.4 mg\dL female ≥1.5 mg\dL male ) Planned coronary intervention plan surgical intervention ( PCI CABG ) Planned surgical intervention Recent ( &lt; 30 day ) acute coronary syndrome ( ACS ) Hypersensitivity either study drug component History lactic acidosis Type I diabetes Current Hb A1c &gt; 9 % Current Insulin treatment Active treatment GLP1 DPP4i medication Hepatic impairment ALT\AST elevation beyond X2 upper normal limit know hepatic failure Inability comply study protocol Active malignancy basal cell carcinoma ( BCC ) Clinically advance congestive heart failure NYHA IIIIV Severe leave ventricular dysfunction ( LVEF &lt; 30 % ) NYHA II NYHA class document recent heart failure decompensation ( &lt; 3 month ) Severe stable cardiac angina CCS III IV Unstable angina Chronic inflammation ( i.e . IBD , Lupus , inflammatory arthritis , rheumatoid arthritis ) chronic infection ( i.e . chronic diabetic foot infection ) Pregnancy , lactation childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>vildagliptin</keyword>
	<keyword>metformin</keyword>
	<keyword>atherosclerosis</keyword>
	<keyword>inflammation</keyword>
	<keyword>interleukin-6</keyword>
	<keyword>TNF</keyword>
	<keyword>atherothrombosis</keyword>
	<keyword>adiponectin</keyword>
	<keyword>MMP-9</keyword>
	<keyword>hs-CRP</keyword>
</DOC>